Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CSL324 in Healthy Japanese and White Subjects
NCT04570267Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Oct 2020
- Primary completion
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anumigilimab in hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP) (3 arms), sponsored by CSL Limited. Primary endpoints: Maximum concentration, Area under the concentration-time curve from time 0 extrapolated to time infinity and 1 more. Started Oct 2020; status: completed.
02
Drugs
anumigilimab
03
Conditions
hidradenitis suppurativa (HS)palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04570267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570267.